Ventyx Biosciences (NASDAQ:VTYX) slid 10% on Tuesday after the biotech firm said it will postpone the interim analysis from its Phase 2 study in recurrent pericarditis until the first quarter of 2026.
The California-based drug developer, which is working on oral treatments targeting inflammation-driven diseases, updated its previous timeline for the release of topline findings. The company now expects to share interim data during its R&D Day planned for early 2026.
CEO Raju Mohan said the revised schedule represents a “modest shift” from earlier expectations but creates room to add dose-ranging work using a new once-daily version of the drug within the ongoing Phase 2 trial. Mohan also noted that opening additional sites in Canada, the EU and the UK should help speed up preparations for Phase 3.
The Phase 2 trial is studying VTX2735, Ventyx’s peripherally restricted NLRP3 inhibitor, in patients suffering from recurrent pericarditis — a chronic inflammatory condition affecting the membrane around the heart that can cause intense chest pain and cardiac complications.
Ventyx also expanded its advisory team, naming Mark McKenna — founder and CEO of Mirador Therapeutics — as Strategic Advisor, along with Dr. Peter Libby of Mass General Brigham Heart & Vascular Institute as Clinical Advisor.
Beginning in December, the company plans to transition the study to a once-daily dosing schedule. The primary endpoint will continue to be evaluated at week 6, while the extension phase has been lengthened to run through 24 weeks.